Spectrum Health Regional Laboratory is pleased to announce NGAL as a new in-house test, effective Tuesday, March 5, 2019.
Urine NGAL concentration is an early biomarker of acute kidney injury that is highly sensitive to early injury and is a marker of tubular-specific damage. Urine NGAL is elevated well before serum creatinine, allowing for prediction of renal tubular injury and possible intervention. It increases quantitatively and proportionally according to the severity of renal structural acute kidney injury.
Questions may be directed to Dr. Jennifer Stumph via the “contact us” link above.
NGAL (Neutrophil Gelatinase-Associated Lipocalin) – Test Codes: Epic #LAB1230499 – CPT #83520 – Interface #1230499
Kidney Int Rep (2017) 2, 1243–1249; http://dx.doi.org/10.1016/j.ekir.2017.05.012